Greenway Health (NYSE: GWAY) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.
This table compares Greenway Health and Omnicell’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Greenway Health and Omnicell, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Omnicell has a consensus price target of $55.14, indicating a potential upside of 6.66%.
Valuation & Earnings
This table compares Greenway Health and Omnicell’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Omnicell has higher revenue and earnings than Greenway Health. Omnicell is trading at a lower price-to-earnings ratio than Greenway Health, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
99.6% of Omnicell shares are owned by institutional investors. 3.8% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Omnicell beats Greenway Health on 5 of the 8 factors compared between the two stocks.
Greenway Health Company Profile
Greenway Health LLC is a United States-based company, which provides clinical, financial and administrative solutions for healthcare providers. The Company provides integrated clinically driven revenue cycle management and electronic health record (EHR) solutions. Its suite of solutions and services is PrimeSUITE, which integrates clinical, financial and administrative data in a single database to enable views of patient records and workflow throughout each patient encounter, reduce clinical and administrative errors, and allow for the exchange of data between its customers and the healthcare community. It offers its solutions by offering managed business services, such as clinically-driven revenue cycle and EHR-enabled research services.
Omnicell Company Profile
Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.
Receive News & Ratings for Greenway Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenway Health and related companies with MarketBeat.com's FREE daily email newsletter.